Abstract
Preeclampsia (PE) is one of the leading causes of maternal morbidity and mortality worldwide. PE is diagnosed by new onset hypertension and proteinuria or end-organ damage at or after mid-gestation. Although it is known that excessive maternal inflammation contributes to PE, the underlying mechanisms that cause hypertension during pregnancy are still unclear. Excessive maternal inflammation may be in part mediated by ligation of Toll-like receptors (TLRs) by pathogen- or danger-associated molecular patterns. MicroRNAs are small endogenous regulators of gene expression and recently numerous inflammation-related microRNAs have been identified. Several clinical studies reported that miR-155 expression, which is known to regulate inflammation in various disease conditions, is also up-regulated in the placentas of women with PE. We confirmed by qRT-PCR that miR-155 expression was significantly increased in formalin-fixed paraffin-embedded placentas from patients with PE compared to normal pregnant women. Poly I:C (a TLR3 agonist) treatment of human placental cytotrophoblasts (CTBs) for 24 hours significantly increased miR-155 expression compared to vehicle-treated CTBs. Based on these data we hypothesized that TLR3 activation induces placental miR-155 expression which in turn contributes to excessive maternal inflammation leading to PE whereas miR-155 deficiency will attenuate PE-like symptoms in a TLR3-induced PE mouse model. Pregnant WT and miR-155 KO mice were treated with poly I:C or saline on gestational days (gd) 13, 15, and 17 prior to sacrifice on gd 18. Poly I:C treatment induced hypertension in pregnant WT mice (P-PIC WT) (gd 17 SBP: 139±4 mmHg) compared to P WT mice (99±4 mmHg), however this was attenuated in P-PIC miR-155 KO mice (100±1 mmHg ). P-PIC WT mice exhibited endothelial dysfunction and splenomegaly compared to P WT mice and these were also attenuated in PPIC miR-155 KO mice. Our data taken together suggest that miR-155 plays a role in the pathogenesis of PE likely by increasing the maternal inflammatory response.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.